Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of epcoritamab versus investigator's choice chemotherapy in relapsed or refractory diffuse large B-cell lymphoma
2023-504830-23-00Phase 3Authorised
- Sponsor
- Genmab
- Start
- Feb 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, follicular lymphoma (FL) and 2 more (2 arms), sponsored by Genmab. Primary endpoints: Overall survival and Progression-free survival by independent review. Planned start Feb 2024; status: authorised.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2023-504830-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504830-23-00.